Vivus' Date With Destiny

Vivus is about to have its moment of truth, after a three-month delay helped competitor Arena slide into an early lead to the market. Will the FDA shine favorably on Vivus and give Qnexa a relatively clean approval, or will the drug be a non-starter because of overly restrictive labeling? Watch and find out what it all means for investors.

Instead of putting all of your eggs in the biotech basket, why not diversify into some solid dividend-paying companies? Fortunately, the Dow is loaded with companies with strong dividend payouts and highly sustainable business models built for the long haul. The 3 Dow Stocks Dividend Investors Need all have an X factor that makes them stand out from their illustrious Dow peers. Download our special free report on these three companies by clicking here.

The article Vivus' Date With Destiny originally appeared on

David Williamsonholds no position in any company mentioned. Check out hisholdings and a short bio. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. Try any of our Foolish newsletter servicesfree for 30 days. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.